Halozyme Therapeutics Inc (HALO)
Operating profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Operating income | US$ in thousands | 551,475 | 337,574 | 267,531 | 275,902 | 144,255 |
| Revenue | US$ in thousands | 1,015,320 | 829,253 | 660,116 | 443,310 | 267,594 |
| Operating profit margin | 54.32% | 40.71% | 40.53% | 62.24% | 53.91% |
December 31, 2024 calculation
Operating profit margin = Operating income ÷ Revenue
= $551,475K ÷ $1,015,320K
= 54.32%
The operating profit margin of Halozyme Therapeutics Inc has shown fluctuations over the years based on the data provided. In December 31, 2020, the operating profit margin was at 53.91%, indicating that the company was generating $0.54 in operating profit for every $1 in revenue. This margin increased significantly to 62.24% by December 31, 2021, reflecting improved efficiency and cost management.
However, there was a decline in the operating profit margin in the following years. By December 31, 2022, the margin dropped to 40.53%, which could be a result of increased operating expenses or a decrease in revenue growth. The margin remained relatively steady in December 31, 2023, at 40.71%, suggesting that the company was able to maintain profitability levels.
The operating profit margin saw a rebound by December 31, 2024, reaching 54.32%. This improvement may signal enhanced operational performance or better revenue management strategies. Overall, the fluctuations in the operating profit margin of Halozyme Therapeutics Inc demonstrate the company's ability to adapt to changing market conditions and optimize its profitability over the years.
Peer comparison
Dec 31, 2024